The Shift-AHEAD review is ongoing so we need to look forward to the study being full or interim results become obtainable before we know if or how properly molnupiravir prevents COVID-19. Thus molnupiravir isn't licensed to circumvent COVID-19. An additional research identified uncoupling in scarce TnC variants determined in DCM: https://elamipretidetriacetate77654.thechapblog.com/27628166/the-definitive-guide-to-clazosentan